For over 30 years, Healius has led the way in supporting quality, affordable and accessible healthcare for all Australians.
Healius has leading market positions and scalable platforms in its diagnostic businesses, along with a growth platform in Australian clinical research where demand is expected to growing the coming years. With a continued focus on margin improvement, organic growth and investment in information technology infrastructure, Healius represents an exciting opportunity for investors both now and in the future.
Healius is one of the country's largest pathology providers, with one in every three pathology samples taken and tested in our laboratories. Our diagnostic imaging business provides approximately three million exams each year, operating from over 140 sites Australia-wide based in public and private hospitals, medical centres and community sites.
This development is influenced by trends in:
This is why the core of Healius’ strategy is to support the delivery of good health outcomes for patients and attractive investment and growth opportunities for our shareholders.
Whether you're a shareholder or not you can subscribe to receive all company announcements.
